Efficacy of amlodipine in pediatric bone marrow transplant patients

Clin Pediatr (Phila). 1998 Jan;37(1):31-5. doi: 10.1177/000992289803700105.


The calcium antagonist amlodipine may have the potential for expanded use in children owing to its physiochemistry and pharmacokinetic profile that facilitates once-daily dosing in a liquid formulation. Its safety and efficacy have not been previously evaluated in children. A retrospective analysis of 15 pediatric bone marrow transplant patients who had amlodipine incorporated into their antihypertensive drug regimen reveals significantly lower blood pressure as compared with baseline therapy (123.5+/-2.1 mmHg and 117.2+/-2.2 mmHg, systolic blood pressure before and during amlodipine, P<0.05; 81.5+/-1.8 mmHg and 75.5+/-2.6 mmHg, diastolic blood pressure before and during amlodipine, P<0.05). Amlodipine provided improved blood pressure control in this cohort and may provide a valuable pharmacologic alternative for treatment of pediatric hypertension.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Age Factors
  • Amlodipine / administration & dosage*
  • Amlodipine / pharmacokinetics
  • Bone Marrow Transplantation*
  • Child
  • Child, Preschool
  • Cohort Studies
  • Female
  • Humans
  • Hypertension / drug therapy*
  • Infant
  • Kidney / drug effects
  • Male
  • Postoperative Care


  • Amlodipine